| Abstract P059 – Table 1. Subjects’ baseline characteristics. | ||||
|---|---|---|---|---|
| Baseline characteristics | Patients (p) (N = 185) | |||
| Age (years) (median ‐ IQR) | 33 (27‐41) | |||
| Gender | Male | 168 (90.8%) | ||
| Gender | Female | 16 (8.7%) | ||
| Gender | Transgender woman | 1 (0.5%) | ||
| HIV transmission | MSM | 156 (84.3%) | ||
| HIV transmission | MSW | 26 (14.1%) | ||
| HIV transmission | IDU | 3 (1.6%) | ||
| Country ‐ region | Spain | 94 (50.8%) | ||
| Country ‐ region | Latin American | 77 (41.6%) | ||
| Country ‐ region | Europe | 6 (3.3%) | ||
| Country ‐ region | Others | 7 (4.3%) | ||
| CD4 cells/mm3 (median ‐ IQR) | Basal CD4+ | 446 (342‐608) | ||
| CD4 cells/mm3 (median ‐ IQR) | CD4 < 200 | 10 (5.4%) | ||
| HIV‐1 VL (c/mL) | ≥ 100,000 c/mL | 45 (24.3%) | ||
| HIV‐1 VL (c/mL) | < 100,000 c/mL | 140 (75.7%) | ||
| Hepatitis B co‐infection | HBsAg + | 0% | ||
| Hepatitis B co‐infection | Anti‐HBc + | 41 (22.2%) | ||
| Hepatitis B co‐infection | Anti‐HBs + | 121 (65.4%) | ||
| Hepatitis C co‐infection (IgG HCV +) | 8 (4.3%) | |||
| HLAB5701 positive | 15 (8.1%) | |||
| Median time from diagnosis to start of treatment (weeks) | 6 (IQR: 2‐12) | |||
| Major mutations in Baseline drug resistance testing (bDRT) | 22 p (11.9%) | INSTIs | 1 p (0.5%) | G163K |
| Major mutations in Baseline drug resistance testing (bDRT) | 22 p (11.9%) | PIs | 1 p (0.5%) | V82C |
| Major mutations in Baseline drug resistance testing (bDRT) | 22 p (11.9%) | NNRTIs | 17 p (9.2%) | E138A(5), K103N(8), V1061(3), V108Vi(2), E138EG, E138E, G190A(2) |
| Major mutations in Baseline drug resistance testing (bDRT) | 22 p (11.9%) | NRTIs | 5 p (2.7%) | M184V(2), M14L, E44D, T215D, T215C, 210W, 215S |
IQR, interquartile range; MSM, men who have sex with men; MSW, men who have sex with women; IDU, injecting drug users; INSTIs, integrase strand transfer inhibitors; PIs, protease inhibitors; NNRTIs, non‐nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors.